Publication | Closed Access

A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer

Gastrointestinal OncologyMedicineBiliary CancerPathologyMolecular OncologyCancer TreatmentCancer GeneticsOncologyRadiation OncologyCancer Research